Risk of Cardiovascular Events Associated with Inhaled Corticosteroid Treatment in Patients with Chronic Obstructive Pulmonary Disease: A Meta-Analysis

<div>Meta-analysis of RCTs of ICSs versus controls for risk of CV events. (a) ICS + LABA versus LABA; (b) ICS + LABA versus LAMA + LABA; (c) ICS versus placebo. LABA: long-acting <i>β</i><sub>2</sub> agonist; LAMA: long-acting muscarinic agonist.</div>

Canadian Respiratory Journal

fig2

Figure 2

Figure 2: Risk of Cardiovascular Events Associated with Inhaled Corticosteroid Treatment in Patients with Chronic Obstructive Pulmonary Disease: A Meta-Analysis 

Figure 2 | Risk of Cardiovascular Events Associated with Inhaled Corticosteroid Treatment in Patients with Chronic Obstructive Pulmonary Disease: A Meta-Analysis 